Long-term Maintenance Combination Chemotherapy with OPECMPEC (Vincristine or Methotrexate, Prednisolone, Etoposide and Cyclophosphamide) or with Daily Oral Etoposide and Prednisolone Can Improve Survival and Quality of Life in Adult T-cell LeukemiaLymphoma
- 1 January 1999
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 36 (1-2) , 67-75
- https://doi.org/10.3109/10428199909145950
Abstract
Acute leukemia and lymphoma varieties of adult T-cell leukemiallymphoma (ATL) usually cany a poor prognosis. While etoposide is generally useful for treating ATL, especially as a daily oral maintenance regimen, etoposide has not proven effective in severe types of ATL efficient in some patients. Of 87 ATL patients whom we have treated, 51 had acute leukemia, 22 lymphoma and 14 progressive chronic leukemia. Seventy-nine patients were treated with a long term maintenance combination rotocol, OPEClMPEC (weekly doses of vincnstine, 0.7 mg/m2 or methotrexate, 14 mg/m; prednisolone, 20 mg/m2; etoposide, 70 mg/m2 and cyclophosphamide, 200 mg/m2). The other 8 patients, 3 with acute leukemia, 2 with lymphoma and 3 with progressive chronic leukemia, were treated with daily oral administration of 25 mg of etoposide and 10 mg of prednisolone (DOEP). The dose administered was modified in individual cases to maintain the granulocyte count and reduce the number of ATL cells. Considering both protocols, a complete response and a partial response were achieved in 31.0% and 58.6% patients, respectively. Median survival times (MST) of all patients and, acute leukemia, lymphoma and progressive chronic leukemia types were 7.5, 6.7, 9.6 and 12.4 months, respectively. Respective MST of patients treated with OPECNPEC or DOEP protocols were 7.1 and 18.0 months. Relatively normal WBC counts, lower lactate dehydrogenase concentration and normal calcium concentration, limited numbers of anatomic sites involved, good performance status and good response to chemotherapy were significantly associated with long survival time. Drug toxicity was not apparent, and about half of patients were treated in an outpatient setting.Keywords
This publication has 23 references indexed in Scilit:
- Granulocyte‐colony stimulating factor‐induced proliferation of primary adult T‐cell leukaemia cellsBritish Journal of Haematology, 1997
- An Intensive Chemotherapy of Adult T-Cell Leukemia/Lymphoma: CHOP Followed by Etoposide, Vindesine, Ranimustine, and Mitoxantrone with Granulocyte Colony-Stimulating Factor SupportJAIDS Journal of Acquired Immune Deficiency Syndromes, 1996
- Combination Chemotherapy (RCM Protocol: Response-Oriented Cyclic Multidrug Protocol) For the Acute or Lymphoma Type Adult T-cell LeukemiaLeukemia & Lymphoma, 1995
- Successful treatment of a patient with adult T-cell leukemia by daily oral administration of low-dose etoposide. Decrease in the amount of HTLV-I proviral DNA revealed by the polymerase chain reaction methodCancer, 1993
- Characteristics of chemotherapy-induced clinical remission in long survivors with aggressive adult T-cell leukemia/lymphomaLeukemia Research, 1993
- Major prognostic factors of patients with adult T-cell leukemia-lymphoma: A cooperative studyLeukemia Research, 1991
- Variation in the clinical courses of adult T-cell leukemiaCancer, 1985
- Human adult T-cell leukemia virus: complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA.Proceedings of the National Academy of Sciences, 1983
- Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease.Proceedings of the National Academy of Sciences, 1982
- Interpretation of Serum Calcium in Patients with Abnormal Serum ProteinsBMJ, 1973